Patent application number | Description | Published |
20110009410 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 01-13-2011 |
20110021521 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-27-2011 |
20120004267 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 01-05-2012 |
20120010192 | Fused Heterocyclic Compounds as Ion Channel Modulators - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-12-2012 |
20120289493 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 11-15-2012 |
20130012521 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 01-10-2013 |
20130035339 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 02-07-2013 |
20130197037 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITOR - The present invention relates to a compound of formula (I): | 08-01-2013 |
20130203819 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 08-08-2013 |
20140018370 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 01-16-2014 |
20140179663 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 06-26-2014 |
20140303158 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 10-09-2014 |
20150038488 | SYK INHIBITORS - The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I | 02-05-2015 |
20150080370 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 03-19-2015 |
20150175597 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ASK1), thus are thus useful in treating ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases. | 06-25-2015 |
20150246910 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 09-03-2015 |
20150329558 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 11-19-2015 |
Patent application number | Description | Published |
20080234519 | Process For the Manufacture of Aminopolyalkylenephosphonic Acid Compounds - A beneficial method for the manufacture of amino polyalkylene phosphonic acids, under substantial absence of hydrohalogenic acid, is disclosed. The method, in essence, is based on reacting narrowly defined ratios of phosphorous acid, an amino, a formaldehyde in presence of specific ranges of an acid catalyst having a pKa equal or inferior to 3.1. The inventive method is capable of yielding economically and quality operational/capacity advantages, in particular significantly reduced one-step cycle duration under exclusion, of corrosion disadvantages and also is environmentally friendly without requiring, in that respect, anything more than nominal capital expenditures. | 09-25-2008 |
20100063316 | REACTIVE PHOSPHONATES - Novel reactive phosphonate compounds are disclosed corresponding to the structural formula set forth. The reactive moiety is preferably selected from the group of Cl, I, Br, HSO | 03-11-2010 |
20100145066 | PHOSPHONATE COMPOUNDS - Novel phosphonate compounds are disclosed embodying an aminophosphonate moiety and a selected reaction partner. These compounds offer beneficial alternatives, and additional possibilities, to extant phosphonates and are capable of delivering desirable benefits from an application standpoint and from a compatibility standpoint broadly. | 06-10-2010 |
20100174110 | PROCESS FOR THE MANUFACTURE OF ALKYLAMINO ALKYLENE PHOSPHONIC ACIDS - A process for the manufacture of alkylamino alkylene phosphonic acids is disclosed. In detail, a specific phosphonate is reacted with an agent selected to yield an alkylamino moiety substituted by a radical selected from OH, OR′, NH2, NHR′, N(R′) | 07-08-2010 |
20110124533 | METHOD OF SCALE INHIBITION - A method is disclosed to inhibit scale formation in aqueous systems whereby a threshold amount of a scale inhibiting agent, represented by an aminoacid alkylphosphonic acid, is added to the aqueous system. The aminoacid moiety can be represented by α-species or by species having, at least, two or more carbon atoms between the carboxylic moiety and the amine group. These aminoacid based inhibitors exhibit unusually superior performance and system acceptability compared to leading state-of-the-art inhibitors. | 05-26-2011 |
20140336408 | PROCESS FOR THE MANUFACTURE OF ALKYLAMINO ALKYLENE PHOSPHONIC ACIDS - A process for the manufacture of alkylamino alkylene phosphonic acids is disclosed. In detail, a specific phosphonate is reacted with an agent selected to yield an alkylamino moiety substituted by a radical selected from OH, OR', NH | 11-13-2014 |